Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial

Effect of early treatment with polyvalent immunoglobulin on acute respiratory distress syndrome associated with SARS-CoV-2 infections (ICAR trial): study protocol for a randomized controlled trial

Abstract Background As of mid-June 2020, 7,500,000 people were infected with SARS-CoV-2 worldwide and 420,000 people died, mainly from coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS). COVID-19-related ARDS is subject to a mortality rate of 50% and prolonged per...

Full description

Bibliographic Details
Main Authors: Aurélien Mazeraud, Bruno Gonçalves, Philippe Aegerter, Letizia Mancusi, Christine Rieu, Fernando Bozza, Khaoussou Sylla, Shidasp Siami, Tarek Sharshar
Format: Article
Language:English
Published: BMC 2021-02-01
Series:Trials
Subjects:
Acute respiratory distress syndrome
COVID-19
SARS-CoV-2
Polyvalent immunoglobulin
Online Access:https://doi.org/10.1186/s13063-021-05118-7

Internet

https://doi.org/10.1186/s13063-021-05118-7

Similar Items